Interview: Mr. Thomas Marchand

“For me, the biggest impact will be the opportunity for surgeons to de-risk their complex operations by training the day before on their patient’s 3D printed organ twin.”

blank

Thomas Marchand is a French entrepreneur. He founded his first startup in the services area sold to market leader in 2014. In 2015, he founded BIOMODEX with Sidarth Radjou (Biomechanical Engineer from Centrale Paris). This Medtech startup develops 3d printed synthetic organs from CT scan for surgery & interventional training.Mr. Marchand will be a speaker at #3DHEALS2017.

 
 
Q: What is your vision on the intersection of 3D Printing and healthcare?

A: 3D printing offers two huge values for me in the healthcare space. First, this amazing technology allows us to model very complex organic shapes that can’t be fabricated with another manufacturing technology. Second, 3D printing is the first way today to manufacture patient-specific prosthesis, surgical guides or models for pre-operative training.

Q: What is the biggest potential impact you see 3D printing (or bioprinting) having on the healthcare industry?

A: For me, the biggest impact will be the opportunity for surgeons to de-risk their complex operations by training the day before on their patient’s 3D printed organ twin.

Q: What challenges do you see arising in implementing 3D printing (or bioprinting) in the healthcare sector in the next five years?

A: The huge stake is to be able to understand how to use currently available materials in 3D printing to reproduce targeted mechanics for custom made prosthesis or models that must react the same (way) as real organs to be relevant to clinical applications.

Q: Who inspires you the most in the 3D printing industry?

A: Everybody’s inspiring! I mean we all have a responsibility to spread the technology, innovate, and make this market grow together.

Q: What is the best business lesson you have learned?

A: Every move you make must create value.

Q: What is the biggest business risk you have taken?

A: Leading a Medtech startup is a risk on its own!

blank

 

Comments